Project Manager/Clinical Research Coordinator

Olga E. Campbell-Ulloa

**** ****** *****

Converse, TX 78109

Mobile: 562-***-****

EDUCATION:

Graduate Universidad Nacional Autonoma de Nicaragua 1994-2004

Physician’s and Surgeon’s Licensure

(Managua, Nicaragua, Central America)

High School Robert A. Millikan, Long Beach, CA 1989-1992

TRAINING AND CERTIFICATIONS

• IATA

• BLS

• OSHA

• Oracle 4.5.3

• Inform 4.6

• Medidata

• Spirometry

PROFESSIONAL EXPERIENCE AS A RESEARCH COORDINATOR

Clinical Trials of Texas Jun2011-Dec2011

7940 Floyd Curl Dr. #700

San Antonio, TX 78229

Discovery Clinical Trials Nov. 2010-May2011

7500 Barlite Blvd#106

San Antonio, TX 78224

California Research Medical Group June 2009-Sep 2010

301 W. Bastanchury Road. Suite 220

Fullerton, CA 92835

Long Beach Center for Clinical Research Aug. 2007-May2009

2865 Atlantic Avenue, suite 227

Long Beach, CA 90806

West Coast Clinical Trials (Phase 1) Feb. 2006-Jan. 2007

5630 Cerritos Ave.

Cypress, CA 90603

OTHER PROFESSIONAL EXPERIENCE

ROBLESSA Sept.-Oct./2005

Elias Lanuza, MD

Los Robles, Managua, Nicaragua

Duties: Physician

CQMUSA Apr.-Jul./2005

Enrique Chavarria, MD

Bello Horizonte, Managua, Nicaragua

Duties: Physician

INEDEH Feb.2003/Nov. 2004

Dr. Alvaro Lacayo Arguello, MD

Bolonia, Managua, Nicaragua

Physician/English teacher

Duties: English teacher for the National Psychiatric Hosptial “Jose Dolores Fletes”

RESEARCH EXPERIENCE

• A randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of two doses of XXX compared with placebo for 12 weeks in patients with moderate to severe, stable chronic obstructive pulmonary disease followed by a 40-week evaluation of the two XXX doses.

• A 12 week randomized multiple dose, double-blind, placebo-controlled, parallel-group trial to assess the pharmacodynamic response of XXX in fixed-dose combination with XXX in subjects with chronic obstructive pulmonary disease.

• A 52-week treatment, randomized, double-blind, placebo-controlled, with open label XXX, parallel group study to assess the efficacy, safety and tolerability of XXX in patients with chronic obstructive pulmonary disease.

• A randomized, double-blind, placebo-controlled, two period, cross-over study to assess the efficacy and safety of differing doses of XXX administered either once daily or twice daily in patients with moderate to severe chronic obstructive pulmonary disease.

• A phase four, multicenter, double-blind, randomized, placebo-controlled study of the safety and tolerance of XXX in subjects with renal impairment.

• A phase four, multicenter, double-blind, randomized, placebo-controlled study of the safety and tolerance of XXX in subjects with Asthma or chronic obstructive pulmonary disease.

• A Large Simple Safety Study of XXX Inhalation Solution in Subjects with Chronic Obstructive Pulmonary Disease.

• A long term, randomized, double-blind study of the safety, tolerability and efficacy of XXX at two dosage levels when administered to patients with moderate to severe stable chronic obstructive pulmonary disease.

• A randomized, active controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5mcg and 5mcg XXX inhalation solution delivered by the XXX inhaler with XXX inhalation capsules 18mcg delivered by the XXX.

• Lead Coordinator for an open label, randomized, multi-site study to assess the pharmacokinetics of single subcutaneous injections of a drug administered at three different injection sites in adult males and female subjects with type 2 diabetes, and a single subcutaneous injections administered in the abdomen of healthy, normal volunteers.

• Lead Coordinator for a phase I, randomized, open label, single dose, three-way crossover, pharmacokinetic study comparing plasma exposure of three different drugs in healthy Chinese, Japanese and Caucasian volunteers.

• Assistant coordinator for a pilot, randomized, open-label, single dose, three way crossover, pharmacokinetic study under fasting conditions comparing two formulations of dry powder for inhalation, versus the reference listed drug in healthy volunteers.

• Assistant coordinator for a phase IV, randomized, double blind, controlled study comparing the allergenicity and immunogenicity of repeated intradermal and subcutaneous injections of two different study drugs in healthy volunteers.

• Assistant coordinator in a phase I, randomized, double blind, placebo-controlled, single intravenous dose escalation, to evaluate the safety, tolerance and pharmacokinetics of the drug in healthy American-Japanese subjects.

• Laboratory processing for a phase I, randomized, single dose, two period, two sequence, two treatment, cross-over, clinical study of the generic version of a nasal spray versus the reference listed drug, for determination of bioequivalence.

• Laboratory processing for a phase I exploratory study of an injection to design therapeutic dosing for chronic active HCV patients.

• Laboratory processing for a study to characterize the dose linearity in pharmacokinetics of two formulations of a drug for three single doses and its pharmacokinetic profile in the presence of food in healthy subjects.

• An 8-week, Randomized, bouble-blind, parallel group, multicenter, active control study to evaluate the antihypertensive efficacy and safety of XXX administered in combination with XXX versus XXX alone in hypertensive patients with type 2 Diabetes Mellitus.

SKILLS

Fluent Spanish/English speaking and writing.

Contact this candidate